Fig 1: Plasma pharmacokinetics of TfRMAb following acute and chronic dosing. WT and FcRn KO mice received acute or chronic four-week dosing of TfRMAb (3 mg/kg SQ). (A) Plasma concentrations (ng/mL) at 3 h, 6 h, and 24 h after acute dosing and (B) after one final dose following chronic dosing. (C) Merged plasma concentration vs. time curves for acute and chronic dosing regimens. (D) Plasma AUC from 0 to 24 h (ng·h/mL) following acute and chronic dosing. Data are shown as the mean ± SEM of n = 4–5 mice per group. * p < 0.05; ** p < 0.01. ns: non-significant.
Fig 2: Plasma pharmacokinetics of TfRMAb-EPO following acute and chronic dosing. WT and FcRn KO mice received acute or chronic four-week dosing of TfRMAb-EPO (3 mg/kg SQ). (A) Plasma concentrations (ng/mL) at 3 h, 6 h, and 24 h after acute dosing and (B) after one final dose following chronic dosing. (C) Merged plasma concentration vs. time curves for acute and chronic dosing regimens. (D) Plasma AUC from 0 to 24 h (ng·h/mL) following acute and chronic dosing. Data are shown as the mean ± SEM of n = 4–10 mice per group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns: non-significant.
Fig 3: Plasma pharmacokinetics of TfRMAb-TNFR following acute and chronic dosing. WT and FcRn KO mice received acute or chronic four-week dosing of TfRMAb-TNFR (3 mg/kg SQ). (A) Plasma concentrations (ng/mL) at 3 h, 6 h, and 24 h after acute dosing and (B) after one final dose following chronic dosing. (C) Merged plasma concentration vs. time curves for acute and chronic dosing regimens. (D) Plasma AUC from 0 to 24 h (ng·h/mL) following acute and chronic dosing. Data are shown as the mean ± SEM of n = 4–5 mice per group. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. ns: non-significant.
Supplier Page from Kactusbio Inc. for Biotinylated Mouse FcRn Protein (FRN-MM401B)